Literature DB >> 19089675

Diagnosis and therapy for neurogenic bladder dysfunctions in multiple sclerosis patients.

Giulio Del Popolo1, Giovanni Panariello, Francesca Del Corso, Giuseppe De Scisciolo, Giuseppe Lombardi.   

Abstract

Neurogenic lower urinary tract dysfunctions are common in patients with multiple sclerosis and for most of them urinary dysfunction has the most negative impact on their social life. No correlation exists between clinical urinary symptoms and urodynamic patterns. Abnormal urodynamic patterns may be present in asymptomatic patients. Both clinical and urodynamic findings may change during the course of the illness. Early diagnostic approach and scheduled follow-ups are mandatory in order to prevent upper urinary tract complications and improve quality of life (QoL).

Entities:  

Mesh:

Year:  2008        PMID: 19089675     DOI: 10.1007/s10072-008-1042-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  22 in total

Review 1.  Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies.

Authors:  Ranan DasGupta; Clare J Fowler
Journal:  Curr Opin Neurol       Date:  2002-06       Impact factor: 5.710

2.  Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis.

Authors:  B L Bemelmans; O R Hommes; P E Van Kerrebroeck; W A Lemmens; W H Doesburg; F M Debruyne
Journal:  J Urol       Date:  1991-06       Impact factor: 7.450

3.  Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism.

Authors:  G Buyse; K Waldeck; C Verpoorten; H Björk; P Casaer; K E Andersson
Journal:  J Urol       Date:  1998-09       Impact factor: 7.450

Review 4.  Oxybutynin in detrusor overactivity.

Authors:  Ananias Diokno; Michael Ingber
Journal:  Urol Clin North Am       Date:  2006-11       Impact factor: 2.241

Review 5.  Multiple sclerosis and the urologist.

Authors:  S E Litwiller; E M Frohman; P E Zimmern
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

6.  Assessment and conservative management of the neuropathic bladder.

Authors:  A M K Rickwood
Journal:  Semin Pediatr Surg       Date:  2002-05       Impact factor: 2.754

7.  Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.

Authors:  Giulio Del Popolo; Maria Teresa Filocamo; Vincenzo Li Marzi; Angelo Macchiarella; Filippo Cecconi; Giuseppe Lombardi; Giulio Nicita
Journal:  Eur Urol       Date:  2007-10-01       Impact factor: 20.096

8.  Intravesical electrotherapy for neurogenic bladder dysfunction: a 22-year experience.

Authors:  Jennifer A Hagerty; Ingrid Richards; William E Kaplan
Journal:  J Urol       Date:  2007-08-17       Impact factor: 7.450

9.  Treatment of neurogenic bladder dysfunction in multiple sclerosis by ultrasound-controlled bladder training.

Authors:  K F Christ; H H Kornhuber
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1980

10.  Maximal external electrical stimulation for treatment of neurogenic or non-neurogenic urgency and/or urge incontinence.

Authors:  G Primus; G Kramer
Journal:  Neurourol Urodyn       Date:  1996       Impact factor: 2.696

View more
  9 in total

1.  Overactive bladder symptoms in patients with multiple sclerosis: Frequency, severity, diagnosis and treatment.

Authors:  Yeşim Akkoç; Murat Ersöz; Nur Yüceyar; Hakan Tunç; Kurtuluş Köklü; Tahir Kurtuluş Yoldaş; Ülkü Dönmez; Cihat Uzunköprü; Ebru Alemdaroğlu; Şule Bilen; Ufuk Emre; Şenay Özdolap; Elif Tuncay; Canan Yücesan; Haydar Gök; Merve Bahar Ercan; Kürşat Uygunol; Belgin Koçer; Murat Zinnuroğlu
Journal:  J Spinal Cord Med       Date:  2016-02-15       Impact factor: 1.985

2.  Caregiver burden among informal caregivers assisting people with multiple sclerosis.

Authors:  Robert J Buchanan; Dagmar Radin; Chunfeng Huang
Journal:  Int J MS Care       Date:  2011

3.  Videourodynamics in patients with neurogenic bladder due to multiple sclerosis: our experience.

Authors:  D Caramella; G Donatelli; N Armillotta; F Manassero; C Traversi; P Frumento; D Pistolesi; C Selli
Journal:  Radiol Med       Date:  2011-01-12       Impact factor: 3.469

4.  Idiopathic giant atonic bladder (6000 mL in volume) present for 15 years with no urinary symptoms.

Authors:  Ahmet Ay; Aydin Demir; Kemal Kismet; Levent Emir; Ertugrul Ertas
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

5.  Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group.

Authors:  A Ghezzi; R Carone; G Del Popolo; M P Amato; A Bertolotto; M Comola; U Del Carro; P Di Benedetto; A Giannantoni; M L Lopes de Carvalho; E Montanari; F Patti; A Protti; S Rasia; A Salonia; C Scandellari; F Sperli; M Spinelli; C Solaro; A Uccelli; M Zaffaroni; V Zipoli
Journal:  Neurol Sci       Date:  2011-12       Impact factor: 3.307

6.  Quality of life in multiple sclerosis patients with urinary disorders: reliability and validity of the Turkish version of King's Health Questionnaire.

Authors:  Yeşim Akkoc; Hale Karapolat; Sibel Eyigor; Hilal Yesil; Nur Yüceyar
Journal:  Neurol Sci       Date:  2011-04-09       Impact factor: 3.307

7.  [Neurogenic or idiopathic destrusor overactivity after failed antimuscarinic treatment : clinical value of external temporary electrostimulation].

Authors:  J Pannek; S Janek; J Noldus
Journal:  Urologe A       Date:  2010-04       Impact factor: 0.639

8.  Clinical Characteristics and Urodynamic Analysis of Urinary Dysfunction in Multiple Sclerosis.

Authors:  Tao Wang; Wei Huang; Yong Zhang
Journal:  Chin Med J (Engl)       Date:  2016-03-20       Impact factor: 2.628

9.  Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study.

Authors:  Magdalena Justyna Kacperska; Karol Jastrzebski; Bartlomiej Tomasik; Jakub Walenczak; Maria Konarska-Krol; Andrzej Glabinski
Journal:  J Mol Neurosci       Date:  2014-12-10       Impact factor: 3.444

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.